RTW Investments’s Soleno Therapeutics SLNO Stock Holding History

RTW Investments’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-424,408	Closed	-$35.6M	–	80
2025 Q2	$35.6M	Buy	+424,408	New	+$31.8M	0.51%	41

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RTW Investments's SLNO Position: Q3 2025 in Review

RTW Investments sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 424,408 shares — an estimated $35.6M sold.

RTW Investments first reported a position in SLNO in Q2 2025 and held it in 1 quarter. The position peaked at $35.6M in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

RTW Investments reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
RTW Investments sold 424,408 Soleno Therapeutics shares in Q3 2025, an estimated $35.6M.
RTW Investments first reported a position in Soleno Therapeutics in Q2 2025 and held it in 1 quarter.
RTW Investments's Soleno Therapeutics position peaked at $35.6M in Q2 2025.
240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on RTW Investments's 13F filing for Q3 2025, filed 14 Nov 2025.